View Medicaid Unwinding Resources

View Maternal Health Resources

View Health Equity Resources


State Strategies for Costly Drugs with Unconfirmed Clinical Benefits

This commentary examines how recent approval of the Alzheimer’s drug Aduhelm under the U.S. Food & Drug Administration’s  Accelerated Approval Program is controversial for a range of reasons, including its projected impact on state Medicaid budgets which will be required to cover the drug, priced at $56,000 a year, despite inconclusive evidence of its clinical effectiveness. While Aduhelm is the latest prescription drug to make headlines, state Medicaid programs have been seeking policy solutions to address high-cost accelerated approval drugs for some time. 



Sign up to receive short email alerts about new resources.